A significant benefit of PSA screening is the early detection of prostate cancer, but there are several limitations, including (but not limited to) only a small decrease in mortality [4], overdiagnosis and overtreatment [5], and false-positive results [6]. This evidence concerns the gene KLK3 and prostate carcinoma.